PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
PDF) mRNA vaccines — a new era in vaccinology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
Nanotechnology for COVID-19: Therapeutics and Vaccine Research. - Abstract - Europe PMC
PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
Moderna Therapeutics — Wikipédia
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
PDF) Generating an Anti-HIV Vaccine Using Nucleoside-modified mRNA Encoding Envelope
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Crowd fund launched for 'Battlestar Galactica' actor Michael Hogan after brain injury
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
